Premenstrual Dysphoric Disorder
2
Pipeline Programs
4
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
1
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
4 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
ErgomedSepranolone
UCB PharmaLevetiracetam
Clinical Trials (2)
Total enrollment: 482 patients across 2 trials
A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD)
Start: Apr 2018Est. completion: Oct 2020475 patients
Phase 2Completed
Levetiracetam in the Treatment of Patients With Premenstrual Dysphoric Disorder (PMDD)
Start: Nov 2003Est. completion: Oct 20067 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.